Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of C-CAR031 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06590246Phase 2Active, not recruiting
- Sponsor
- AbelZeta
- Start
- Sep 2024
- Primary completion
- Apr 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AZD5851 in hepatocellular carcinoma (HCC), sponsored by AbelZeta. Primary endpoints: Safety and tolerability up to 24 months and Anti-tumor activity up to 24 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
AZD5851
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06590246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590246.